<DOC>
	<DOCNO>NCT01345188</DOCNO>
	<brief_summary>Patients ischemic cardiomyopathy may continue experience persistent chest pain shortness breath despite conventional medical therapy and/or revascularization . The purpose study determine efficacy take Ranexa versus placebo patient ischemic ( due blockage ) cardiomyopathy treat optimal conventional medical therapy and/or percutaneous revascularization .</brief_summary>
	<brief_title>Ranolazine Ischemic Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Chest Pain</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>1 . Ischemic cardiomyopathy patient optimal medical treatment . Optimal medical treatment define continue symptom chest pain dyspnea despite treatment 2 antiischemic agent ( beta blocker , CCB nitrate ) . Unless contraindicate , cardiomyopathy patient treat beta blocker ACEI/ARB . 2 . Anginal chest pain dyspnea 3 . Documentation non treatable optimally treat coronary artery disease 4 . Ejection Fraction less equal 40 % 1 . Less 18 year age 2 . Pregnant breast feed 3 . Patients non ischemic cardiomyopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>